Finding an autoimmune collaborator VX-509 is moving through the pipelines as a rheumatoid arthritis treatment with phase 2b data due later this year. But Vertex hopes to expand into psoriasis and ...

Stocks climbing to 10 times their original price are rare breeds -- but they're not impossible to find. Especially when ... of data by an outside vendor, Vertex's cystic fibrosis treatment ...

Vertex Pharmaceuticals’s non-opioid-based ... The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on ...

Due to its solid fundamentals and expanding pipeline, Vertex is a strong growth stock that should remain a favorite among general investors and long-term holders. It’s a rare growth opportunity ...

The Food and Drug Administration late Thursday approved a new non-opioid pain pill from Vertex Pharmaceuticals, one of the most closely-watched drugs in all of biotech. Now comes the real test ...

It may not be a verified cure for Type 1 diabetes, but it’s a sign that Vertex Pharmaceuticals is at least on the right path toward finding one ... injected at Mass. General Hospital with ...